


Distinction in CHF subtypes

Table 4. Classification of HF by LVEF (Table view)

Type of HF According to LVEF	Criteria
HFrEF (HF with reduced EF)	LVEF ≤40%
HFimpEF (HF with improved EF)	Previous LVEF ≤40% and a follow-up measurement of LVEF >40%
HFmrEF (HF with mildly reduced EF)	LVEF 41%-49% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)
HFpEF (HF with preserved EF)	LVEF ≥50% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)


2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines


Circulation. 2022;145:e1033





Identifying Stages of Heart Failure (ACC/AHA)


- Stage A At risk of heart failure, but without structural heart disease
- Stage B Structural heart disease but without signs or symptoms of heart failure
- Stage C Structural heart disease with prior or current heart failure symptoms
- Stage D Refractory heart failure, requiring specialized intervention.
- These will help in identifying appropriate strategies for management.






















		Diuretics in Treatment of Congestion for Chr	
Drug	Initial Daily Dose	Maximum Total Daily Dose	Duration of Action
Loop diuretics			
Burnetanide	0.5-1.0 mg once or twice	10 mg	4–6 h
Furosemide	20-40 mg once or twice	600 mg	6–8 h
Torsemide	10-20 mg once	200 mg	12–16 h
Thiazide diuretics			
Chlorthiazide	250-500 mg once or twice	1000 mg	6–12 h
Chlorthalidone	12.5-25 mg once	100 mg	24–72 h
Hydrochlorothiazide	25 mg once or twice	200 mg	6–12 h
Indapamide	2.5 mg once	5 mg	36 h
Metolazone	2.5 mg once	20 mg	12–24 h
	н	F indicates heart failure.	
2022 AHA/ACC/HFS	SA Guideline for the Manageme	ent of Heart	
	the American College of Cardio		
















Implantable	Primary prevention of sudden death						
Implantable defibrillator (ICD)	MADIT	1996		Prior MI+LVEF ≤35%+NSVT+inducible nonsuppressible sustained VT/VF on electrophysiological (EP) testing	Defibrillator vs conventional medical therapy	0.46 (<i>P</i> =0.009)	
				Timing:			
				>3 wk post-MI			
				>2 mo post-CABG			
				>3 mo post-PTCA			
	MUSTT	1999		CAD+LVEF ≤40%+Asymptomatic NSVT+Inducible sustained ventricular tachyarrhythmia	EP-guided therapy with AADs or defibrillator or no AA therapy	0.40 (<i>P</i> <0.001)	
				Timing:			
				34 days post-MI or revascularization			
	MADIT	DIT 2002	1232	Prior MI+LVEF ≤30%	Defibrillator vs conventional medical therapy	0.69 (<i>P</i> =0.02)	
	11			Timing:			
				>1 mo post-MI			
				>3 mo postrevascularization			
	DEFINITE	2004	458	Nonischemic cardiomyopathy LVEF< 36%+PVC or NSVT	Defibrillator+standard medical therapy vs medical therapy alone	0.65 (<i>P</i> =0.08)	
		2005	005 2521	NYHA FC II-III+LVEF ≤35%	Defibrillator vs amiodarone vs Placebo	0.77 (<i>P</i> =0.007)	
	SCDHeFT	CDHeFT		Timing:			
				>3 mo heart failure			
	DANISH	2016	6 1116	Nonischemic cardiomyopathy LVEF <35%+NYHA class II or III, or NYHA class IV if CRT was planned+NT-pro BNP>200 pg/ml	Defibrillator vs standard care CRT received in 58% in both groups	0.87 (<i>P</i> =0.28)	
				Timing:			
				After reaching target doses of optimal medical therapy			





- When no additional therapy can be added.
 - Low blood pressure
 - End organ disfunction
 - Congestive hepatopathy
 - Cardiorenal syndrome
 - Cachexia
 - Frequent hospitalizations

- Inotropic medications
 - In evidence of shock (IIB)
- Mechanical circulatory support
 - Temporary (IABP, ECMO)
 - LVAD (DT, Bridge to OHT)
- Orthotopic heart transplantation
- If the patient is not a candidate for the above, hospice should be considered.

I NEED HELP

- I, Intravenous inotropes
- N, New York Heart Association (NYHA) class IIIB to IV or persistently elevated natriuretic peptides
- E, End-organ dysfunction
- E, EF ≤35%
- D, Defibrillator shocks
- H, Hospitalizations >1
- E, Edema despite escalating diuretics
- L, Low systolic BP ≤90, high heart rate
- P, Prognostic medication; progressive intolerance or down-titration of GDMT

